In particular, active treatment with anti-CD38 monoclonal antibodies or anti-BCMA bispecific antibodies was associated with decreased CD4+ T cell responses, while patients treated with anti-BCMA CAR T cells mounted similar CD4+ T cell responses compared to myeloma patients receiving other therapies [115]. The gene discussed is CD38; the disease is plasma cell myeloma.